Impact of IL-33/ST2 signaling pathway and galectin-3 on clinical characteristics of patients with schizophrenia in remission

[S.Minić Janićijević]

85 listova

Shizofrenija i dalje predstavlja jedan od najtežih psihotičnih, deteriorantnih poremećaja hroničnog toka, sa znatnim uticajem na emocionalni i društveni život pacijenata, pogotovo jer su uobičajeni i somatski komorbiditeti, naročito metabolički sindrom i srčane bolesti. Cilj ove studije je bio da se ispita uticaj signalnog puta interleukina-33 i supresora tumorogeneze 2 (IL-33/ST2) i galektina-3 (Gal-3) na kliničke karakteristike pacijenata sa shizofrenijom u remisiji. Poređene su izmerene vrednosti između grupa ispitanika, zatim je ispitivana moguća povezanost serumskih koncentracija IL-33, sST2 i Gal-3 sa drugim merenim citokinima, kao i sa kliničkim skorovima psihijatrijskih skala procene i vrednostima biomarkera kardiometaboličkog rizika u grupi pacijenata sa shizofrenijom u remisiji. Nakon analize dobijenih rezultata, utvrđena je viša serumska koncentracija Gal-3 u grupi pacijenata sa shizofrenijom u remisiji u odnosu na kontrolnu grupu zdravih. Zatim, utvrđeno je da postoji pozitivna korelacija IL-33 sa proinflamatornim citokinima IL-6, IL-23, faktorom nekroze tumora-alfa (engl. Tumor Necrosis Factor-alpha – TNF-α) i IL-1β, pozitivna korelacija sST2 sa TNF-α i IL-1β, kao i pozitivna korelacija Gal-3 sa IL-23, TNF-α i sST2 u grupi pacijenata sa shizofrenijom u remisiji. Utvrđena je i značajna povezanost IL-33 i sST2 sa kliničkim simptomima shizofrenije, IL-33 sa kognicijom, kao i sST2 sa biomarkerima kardiometaboličkog rizika u grupi pacijenata. Možemo da zaključimo da postoji poseban uticaj IL-33/ST2 signalnog puta i Gal-3 na ispitivane kliničke karakteristike kod pacijenata sa shizofrenijom u remisiji. Ova inicijalna analiza novih biomarkera zapaljenja ukazuje na mogućnost novog pristupa u dijagnostici i tretmanu shizofrenije.

Schizophrenia remains one of the most severe psychotic and deteriorating disorders with a chronic course that significantly impacts the emotional and social life of patients, often accompanied by common somatic comorbidities, especially metabolic syndrome and heart diseases. This study aimed to examine the influence of the interleukin-33 and suppressor of tumorigenesis 2 (IL-33/ST2) signaling pathway and galectin-3 (Gal-3) on the clinical characteristics of patients with schizophrenia in remission. Comparison was done between groups, followed by an examination of the possible association of serum concentrations of IL-33, sST2, and Gal-3 with other measured cytokines as well as with the clinical scores of psychiatric assessment scales and with the values of biomarkers of cardiometabolic risk in a group of patients with schizophrenia in remission. After analyzing the results obtained from the study, it was discovered that there is a higher serum concentration of Gal-3 in patients with schizophrenia who are in remission when compared to healthy individuals. Additionally, there was a positive correlation between IL-33 and pro-inflammatory cytokines such as IL-6, IL-23, tumor necrosis factor-alpha (TNF-α), and IL-1β. There was also a positive correlation between sST2 and TNF-α and IL-1β. Furthermore, there was a positive correlation between Gal-3 and IL-23, TNF-α, and sST2 in the group of patients with schizophrenia in remission. In the case of IL-33 and sST2, a significant association was found with the clinical symptoms of schizophrenia, IL-33 was associated with cognition and sST2 with biomarkers of cardiometabolic risk in the patient group. It can be concluded that there is a specific effect of the IL-33/ST2 signaling pathway and Gal-3 on the clinical characteristics of patients with schizophrenia in remission. This initial analysis of new biomarkers of inflammation indicates the possibility of a new approach in the diagnosis and treatment of schizophrenia.

shizofrenija, IL-33, sST2, Gal-3, kardiometabolički rizik

schizophrenia, IL-33, sST2, Gal-3, cardiometabolic risk

616.89(043.3)

Psihijatrija

Tekst